You are here

Article Text

Article menu
Download PDFPDF
Scientific letters
Thrombolysis in patients with a brain tumour
  1. R Rubinshtein,
  2. R Jaffe,
  3. M Y Flugelman,
  4. B Karkabi,
  5. B S Lewis
  1. Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center, Haifa, Israel
  1. Correspondence to:
    Dr Ronen Rubinshtein
    Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center, 7 Michal Street, Haifa 34362, Israel; adironennetvision.net.il

https://doi.org/10.1136/hrt.2003.031013

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Many potentially eligible patients (30–50%) with acute ST elevation myocardial infarction (STEMI) do not currently receive thrombolytic treatment, partly because of the presence of a contraindication.1 Intracranial haemorrhage (ICH) is a severe complication of thrombolysis, with high morbidity and mortality, and an incidence of approximately 0.75% in the major thrombolytic trials.2 Subgroup analysis of these trials identified advanced age, female sex, use of alteplase (versus streptokinase), and systemic hypertension as risk factors for ICH.2 Intracranial tumours (ICT) are considered an absolute contraindication for thrombolysis because of their association with spontaneous ICH, although no …

    View Full Text